The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer

Molecular Endocrinology

Volumn 11, Issue 6, 1997, Pages 667-673

  O'Malley Jr , Bert W ^a   Sewell, Duane A ^a   Li, Daqing ^a   Kosai, Ken Ichiro ^c   Chen, Shu Hsia ^b   Woo, Savio L C ^b   Duan, Ling ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; THYMIDINE KINASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GENE THERAPY; HEAD AND NECK CANCER; IMMUNE RESPONSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; TREATMENT OUTCOME; TUMOR REGRESSION;

ADENOVIRIDAE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2; MICE; MICE, INBRED C3H; NEOPLASMS, SQUAMOUS CELL; THYMIDINE KINASE;

ADENOVIRIDAE; ANIMALIA; HERPES;

EID: 8244244603     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.11.6.667     Document Type: Article

References (23)

1. Fearon ER, Pardoll DM, Itaya R, Golumbek P, Levitsky H, Simons J 1990 Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
2. Rosenberg SA, Lotze M, Maul LM 1987 A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897
3. West WH, Touer KW, Yanelli JR 1987 Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905
4. Morgan DA, Ruscetti FW, Gallo R 1976 Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 193:1007-1008
5. Kuribayashi K, Gillis S, Kern DE, Henney CS 1981 Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol 126: 2321-2327
6. Henney CS, Kern DE, Gillis S 1982 Cytotoxic responses: the regulatory influence of interleukin-2. Transplant Proc 14:565-569
7. Henney CS, Kuribayashi K, Kern DE, Gillis S 1981 Interleukin-2 augments natural killer cell activity. Nature 291:335-338
8. Rook AH, Masur H, Lane HC, et al. 1983 Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 72:398-403
9. West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK 1987 Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905
10. Pardoll DM 1993 Cancer vaccines. Immunol Today 14:310-316
11. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E 1990 Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
12. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM 1991 Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713-716
13. De Stefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G 1996 Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J Immunother 19:125-133
14. Kozarsky KF, Wilson JM 1993 Gene therapy: adenovirus vectors. Curr Opin Gen Dev 3:499-503
15. Boucher RC, Knowles MR, Johnson LG, Olsen JC 1994 Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. Hum Gene Ther 5:615-639
16. Rosenfeld MA, Yoshimurea K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Bargon J, Stier LE, Stratford-Perricaudet LD, Perricaudet M, Guggino WB, Pavirani A, Lecocq JP, Crystal RG 1992 In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155
17. Rich DP, Couture M, Carodoza LM, Guiggio VM, Armantano D, Espino PC, Hehir K, Welsh MJ, Smith AE, Gregory RJ 1993 Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther 4:461-476
18. Welsh MJ, Smith AE, Zabner J, Rich DP, Graham SM, Gregory RJ, Pratt BM, Moscicki RA 1994 Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. 5:209-219
19. O'Malley Jr BW, Chen S-H, Schwartz MR, Woo SLC 1995 Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 55:1080-1085
20. O'Malley Jr BW, Cope KA, Chen S-H, Li D, Schwartz MR, Woo SLC 1996 Combination Gene Therapy for Oral Cancer in a Murine Model. Cancer Res 56:1737-1741
21. Chen S-H, Li Chen XH, Wang Y, KosaiK, Finegold MJ, Rich SS, Woo SLC 1995 Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92:2577-2581
22. Chen S-H, Shine D, Goodman JC, Grossman RG, Woo SLC 1994 Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 91:3054-3057
23. Fu KK, Rayner PA, Lam KN 1984 Modification of the effects of continuous low dose irradiation by concurrent chemotherapy infusion, Int J Radiat Oncol Biol Phys 10:1473-1478